Biogen, Sage's postpartum depression approval overshadowed by larger rejection
Fierce Pharma
AUGUST 7, 2023
While an FDA approval is typically cause for celebration, Sage Therapeutics and Biogen have a tough road ahead to market their new postpartum depression (PPD) drug. each year, according to Biogen and Sage. each year, according to Biogen and Sage. Friday, the U.S.
231 
Let's personalize your content